FDA Grants RMAT Designation to Tisagenlecleucel for Relapsed/Refractory Follicular Lymphoma

The FDA granted regenerative medicine advanced therapy designation to tisagenlecleucel for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma.

Source: CancerNetwork - April 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news